Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

All Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases